Ravi Shridhar, MD

BOARD-CERTIFIED RADIATION ONCOLOGIST

Clinical Trial Investigator
Focuses on gastrointestinal, lung and genitourinary cancers
Ravi Shridhar, MD, PhD

Dr. Ravi Shridhar is a board certified radiation oncologist who dedicates his considerable energy and skills to developing effective new radiation therapy techniques for pancreatic and gastrointestinal cancer, including esophageal and liver cancer and cholangiocarcinoma. His extensive research and clinical trials have yielded over 140 published articles, abstracts and poster presentations and helped move forward the battle against these complex and life-threatening diseases. He is an outstanding clinician whose dedication to finding the best treatments for his patients has earned him recognition among the state’s most distinguished cancer specialists.

Before joining Radiation Oncology Specialists, Dr. Shridhar served at the Moffitt Cancer Center in Tampa as Chief of the Radiation Oncology GI Service and Chief of the Theraspheres Radioembolization Service, where he identified and coordinated scheduling and radiation dosing for patients requiring revolutionary Theraspheres treatment and initiated clinical trials. He was also an Assistant Professor of Oncologic Sciences at the University of South Florida Morsani College of Medicine in Tampa.

Dr. Shridhar’s extensive educational background includes his PhD and Medical Degree, earned simultaneously at Wayne State University in Detroit, MI, along with his internship in internal medicine at William Beaumont Hospital in Royal Oak, MI and Residency in radiation oncology at Wayne State University’s Detroit Medical Center/Karmanos Cancer Institute.

Specialties

  • Adenocarcinoma
  • Adjuvant Radiotherapy
  • Anal Neoplasms
  • Bone Cancer
  • Brachytherapy
  • Chemoradiotherapy
  • Cholangiocarcinoma
  • Colorectal Cancer
  • Combined Modality Therapy
  • Conformal Radiotherapy
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • General Radiation Oncology
  • Image-guided Radiotherapy
  • Metastatic Cancer
  • Pancreatic Cancer
  • Prostate Cancer
  • Radiation Therapy
  • Stereotactic Radiosurgery

Grants, Research & Clinical Trials

  • Primary Investigator, Validation of a Radiation Response Signature in Borderline Resectable Pancreatic Cancer Patients Treated with Induction Chemotherapy followed by Stereotactic Body Radiation Therapy
  • Primary Investigator, Phase II Study of Intrahepatic Arterial Inection of 90-Y Glass Microspheres as First Line Treatment for Cholangiocarcinoma
  • Primary Investigator, A Phase II Clinical Trial Evaluating Overall Survival with Therasphere® in Conjuction with 2nd Line FOLFOX in Patients with Gemcitabine-Refractory Pancreatic Carcinoma with Liver Metastases

Publications

  • Co-author, The Impact of Lymph Node Harvest in Esophageal Cancer After Neoadjuvant Radiotherapy; a SEER Database Analysis
  • Co-author, Effect of Body Mass Index in Patients Undergoing Resection for Gastric Cancer: A Single Center US Experience
  • Co-author, Adjuvant Radiotherapy and Lymph Node Dissection in Pancreatic Cancer Treated with Surgery and Chemotherapy
(407) 588-9050